2023-509961-19-00已完成1 期
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
EU Submission Hub
Scientific
Novo Nordisk A/S
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A research study of a new medicine NNC0519-0130 in Japanese and non-Japanese metype 2 diabetesJPRN-jRCT2071230015Tsukasaki Nobuaki70
已完成
不适用
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral dosing in healthy subjects including brain Serotonin Transporter (SERT) occupancy by Positron Emission Tomography (PET).chronische pijn aan beschadigde organen.visceral painNL-OMON34068Eli Lilly51
招募中
1 期
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235JPRN-jRCT2021220012Shiga Tohru18
尚未招募
1 期
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)
已完成
不适用
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orallyNL-OMON48072OP2 Drugs12